Noradrenaline (Norepinephrine) Laboratoire Aguettant (Noradrenaline Tartrate)

Norepinephrine, the active ingredient in Noradrenaline (Norepinephrine) Laboratoire Aguettant, is a sympathomimetic agent presented as an intravenous solution for intravenous administration. It is used to raise blood pressure and improve cardiac output in patients with acute hypotension, cardiogenic shock or septic shock.

GNH USA supplies Noradrenaline (Norepinephrine) Laboratoire Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and intensive‑care units worldwide, with distribution across the EU and other regulated markets. All batches meet European Pharmacopoeia standards and are shipped under controlled temperature conditions.

Noradrenaline (norepinephrine) is a sympathomimetic cardiovascular agent used to manage severe hypotensive states.

- Hypotension: restores vascular tone and raises arterial pressure in acute hypotensive episodes, aiding organ perfusion. - Cardiogenic shock: enhances myocardial contractility and systemic vascular resistance, improving cardiac output and tissue oxygen delivery in pump failure. - Septic shock: counteracts profound vasodilation by stimulating alpha‑1 receptors, supporting blood pressure and organ perfusion during systemic infection.

Norepinephrine may be associated with a range of adverse reactions, varying from frequent to rare.

Common Side Effects: - Headache: mild to moderate headache reported during infusion. - Tachycardia: increased heart rate due to beta‑1 stimulation. - Arrhythmia: occasional premature beats or rhythm disturbances. - Peripheral ischemia: reduced blood flow to extremities causing coldness or pain. - Nausea: occasional nausea or vomiting.

Serious or Rare Side Effects: - Severe hypertension: abrupt, excessive rise in blood pressure. - Myocardial ischemia: chest pain or infarction from increased cardiac workload. - Tissue necrosis: extravasation at infusion site leading to local tissue damage. - Pulmonary edema: fluid accumulation in lungs due to fluid shifts. - Anaphylaxis: rare hypersensitivity reaction with rash, bronchospasm, hypotension.

When using norepinephrine, clinicians should observe specific safety measures to minimize risks. - Dose titration: adjust infusion rate based on continuous blood pressure monitoring. - Cardiac monitoring: observe for arrhythmias and signs of myocardial ischemia. - Extravasation risk: avoid peripheral administration; use central venous line when possible. - Fluid status: ensure adequate intravascular volume before initiating therapy. - Concomitant vasopressors: evaluate cumulative pressor effect when combined with other agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Norepinephrine can interact with several drugs, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: may potentiate hypertensive response. - Tricyclic antidepressants: increase risk of severe hypertension. - Beta‑blockers: can blunt desired tachycardia and reduce cardiac output.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: may enhance vasodilatory effects, requiring dose adjustment. - Diuretics: can exacerbate intravascular volume depletion, affecting response. - Sedatives or anesthetics: may mask signs of excessive pressor effect.